Depression Interactive Interpreter

PHQ-2 Depression Screener (Patient Health Questionnaire-2)

2-item ultra-brief depression screener. Score ≥3 indicates need for full PHQ-9 evaluation.

PHQ-2 Screening Result Interpreter

Positive screen

Score ≥3 indicates a positive screen. Proceed to full PHQ-9 and clinical evaluation; ask directly about suicidal ideation. The PHQ-2 alone is not sufficient to diagnose depression.

2 items (depressed mood, anhedonia), each scored 0–3 based on frequency in the past 2 weeks. Total range 0–6. A single cutoff of ≥3 identifies a positive screen.

Total scoreInterpretation
3+Positive screenScore ≥3 indicates a positive screen. Proceed to full PHQ-9 and clinical evaluation; ask directly about suicidal ideation. The PHQ-2 alone is not sufficient to diagnose depression.
0–2Negative screenScore below 3 is a negative screen. The PHQ-2 has a high negative predictive value, though clinical judgment should guide further assessment when suspicion remains high.

Kroenke K, Spitzer RL, Williams JBW. Med Care. 2003;41(11):1284–1292. Cutoff ≥3 identified as optimal screening threshold (sensitivity 83%, specificity 92% against structured clinical interview). Educational reference only — not a diagnostic tool.

The PHQ-2 is a 2-item depression screener derived from the PHQ-9. With a score range of 0–6 and a ≥3 positive threshold, it identifies patients who need the full PHQ-9 in under 1 minute.

What is the PHQ-2?

The PHQ-2 (Patient Health Questionnaire-2) consists of the first two questions of the PHQ-9, assessing the two core symptoms of major depressive disorder: anhedonia (loss of interest or pleasure) and depressed mood. Developed from the PRIME-MD diagnostic tool and validated by Kroenke et al. (2003), it is the recommended first-step depression screen in primary care, behavioural health integration, and population health programs.

Each item is rated 0–3 based on symptom frequency over the past 2 weeks (Not at all / Several days / More than half the days / Nearly every day), yielding a total score of 0–6. A score of 3 or higher is a positive screen and indicates the need for full PHQ-9 administration and clinical evaluation.

The PHQ-2 is part of the PHQ family of tools (PHQ-9, PHQ-A, PHQ-SADS) developed by Drs. Spitzer, Kroenke, and Williams. It is freely available in the public domain and widely endorsed by USPSTF, APA, and primary care guidelines internationally.

PHQ-2 is a Gateway Screen, Not a Standalone Diagnostic

A positive PHQ-2 (≥3) requires follow-up with the full PHQ-9 and clinical evaluation. The PHQ-2 alone is not sufficient to diagnose depression or determine severity. It is designed as an efficient first step to identify who needs further assessment.

Public Domain

The PHQ-2 is in the public domain. No permissions, licensing fees, or royalties are required for clinical, educational, or research use.

The Two PHQ-2 Questions

Both questions ask about the past 2 weeks. Each is rated on a 4-point scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day).

Over the past 2 weeks, how often have you been bothered by little interest or pleasure in doing things?

Depressed Mood

Over the past 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?

Administration Best Practices

  • Administer at intake and as a periodic check at follow-up visits
  • Proceed to PHQ-9 promptly when score ≥3, do not defer to a later visit
  • Can be patient self-administered (paper, tablet, or digital), saving clinician time
  • Always ask about suicidal ideation when PHQ-2 is positive, regardless of PHQ-9 results

Answer both questions based on how often you have been bothered over the past 2 weeks.

PHQ-2 Scoring & Interpretation

Sensitivity & Specificity

At the ≥3 threshold (Kroenke et al., 2003):

  • Sensitivity: 76–83% for major depressive disorder (pooled ~76%, Levis et al. 2020 JAMA meta-analysis; original 2003 study: 83%)
  • Specificity: 78–92% (varies by population)
  • PPV: 54% in primary care populations
  • NPV: 97%, excellent for ruling out depression

When PHQ-2 is Positive (≥3)

Required follow-up steps:

  • Administer full PHQ-9 (9 items) for severity scoring
  • Ask directly about suicidal ideation (PHQ-9 item 9)
  • Conduct clinical interview to assess duration, impairment, and triggers
  • Consider GAD-7 for comorbid anxiety (very common)

Negative PHQ-2 Doesn't Rule Out All Depression

The PHQ-2's NPV of 97% is excellent but not perfect. If clinical suspicion is high (e.g., patient reports sadness, sleep changes, or weight loss), administer the full PHQ-9 regardless of PHQ-2 score. Clinical judgment always supersedes a screening score.

PHQ-2 vs PHQ-9: When to Use Each

The PHQ-2 and PHQ-9 are designed to work together as a two-stage screening and assessment protocol.

Clinical Guidance: The PHQ-2 functions as a triage gate. In high-volume settings (primary care, urgent care, employee health), administer PHQ-2 to all patients. Those who screen positive (≥3) proceed directly to PHQ-9. This two-stage approach reduces patient burden for the ~80% who screen negative while ensuring the PHQ-9's full diagnostic power is applied where it matters. For measurement-based care programs focused on depression treatment monitoring, use PHQ-9 directly at every visit rather than starting with PHQ-2.

Documenting PHQ-2 scores in clinical notes?

PHQ-2 scores belong in the Objective section of your note. See our SOAP notes guide and Intake Notes guide for templates and examples.

Billing the PHQ-2 (CPT 96127)

PHQ-2 administration qualifies for reimbursement under CPT code 96127 (brief emotional/behavioural assessment). The AMA allows up to 4 units per encounter; Medicare limits this to 3 units per encounter. Each unit represents one validated scale administered, scored, and documented. When the PHQ-2 is positive and you escalate to the full PHQ-9, both scales can each be billed as a separate 96127 unit in the same encounter.

Clinical Use:These results are intended to inform clinical decision-making in licensed practice. They do not replace evaluation by a qualified clinician.

Frequently Asked Questions

What is a positive PHQ-2 score?

A PHQ-2 score of 3 or higher is considered a positive screen for depression. This cutoff was identified as the optimal threshold in the original 2003 validation study by Kroenke et al., with a sensitivity of 83% and a specificity of 92% against a structured clinical interview. A positive result indicates the need for full PHQ-9 administration and clinical evaluation.

Can the PHQ-2 diagnose depression?

No. The PHQ-2 is a screening tool, not a diagnostic instrument. A positive screen (≥3) identifies patients who need further evaluation with the full PHQ-9 and a clinical interview. Diagnosis of major depressive disorder requires a comprehensive clinical assessment that considers symptom duration, functional impairment, and differential diagnoses.

Is the PHQ-2 self-report or clinician-administered?

The PHQ-2 is designed as a patient self-report questionnaire. Patients complete it on paper, tablet, or a digital platform without requiring clinician prompting, which makes it practical for routine intake screening in high-volume settings. Scores are then reviewed and acted upon by a clinician.

How is the PHQ-2 scored?

Each of the two items is rated on a 4-point frequency scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), and 3 (Nearly every day). The two item scores are summed for a total score ranging from 0 to 6. A total score of 3 or above is a positive screen.

References

  1. 1.
    Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.View source
  2. 2.
    Levis B, Sun Y, He C, et al.; Depression Screening Data (DEPRESSD) PHQ Collaboration. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. JAMA. 2020;323(22):2290-2300.View source
  3. 3.
    Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;365:l1476.View source

Bill this assessment

The PHQ-2 Depression Screener (Patient Health Questionnaire-2) qualifies for reimbursement under these CPT codes (US).

Last reviewed: Jun 3, 2026